Consistently, moDCs phagocytosed more DOX@3D-MPs-treated tumor cells compared with PBS-treated group (Fig. 8b), leading to their efficient maturation as indicated by the elevated percentages of costimulatory molecules CD80+ (Fig. 8c) and CD86+ cells (Fig. 8d) in moDCs. The gene discussed is CD86; the disease is neoplasm.